Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
Mais filtros











Intervalo de ano de publicação
1.
Sci Rep ; 14(1): 10696, 2024 05 10.
Artigo em Inglês | MEDLINE | ID: mdl-38730068

RESUMO

COVID-19, caused by SARS-CoV-2, affects neuronal cells, causing several symptoms such as memory loss, anosmia and brain inflammation. Curcuminoids (Me08 e Me23) and curcumin (CUR) are derived from Curcuma Longa extract (EXT). Many therapeutic actions have been linked to these compounds, including antiviral action. Given the severe implications of COVID-19, especially within the central nervous system, our study aims to shed light on the therapeutic potential of curcuminoids against SARS-CoV-2 infection, particularly in neuronal cells. Here, we investigated the effects of CUR, EXT, Me08 and Me23 in human neuroblastoma SH-SY5Y. We observed that Me23 significantly decreased the expression of plasma membrane-associated transmembrane protease serine 2 (TMPRSS2) and TMPRSS11D, consequently mitigating the elevated ROS levels induced by SARS-CoV-2. Furthermore, Me23 exhibited antioxidative properties by increasing NRF2 gene expression and restoring NQO1 activity following SARS-CoV-2 infection. Both Me08 and Me23 effectively reduced SARS-CoV-2 replication in SH-SY5Y cells overexpressing ACE2 (SH-ACE2). Additionally, all of these compounds demonstrated the ability to decrease proinflammatory cytokines such as IL-6, TNF-α, and IL-17, while Me08 specifically reduced INF-γ levels. Our findings suggest that curcuminoid Me23 could serve as a potential agent for mitigating the impact of COVID-19, particularly within the context of central nervous system involvement.


Assuntos
Anti-Inflamatórios , Antioxidantes , Antivirais , Tratamento Farmacológico da COVID-19 , Curcumina , SARS-CoV-2 , Humanos , Curcumina/farmacologia , Curcumina/análogos & derivados , Antioxidantes/farmacologia , Antivirais/farmacologia , SARS-CoV-2/efeitos dos fármacos , SARS-CoV-2/fisiologia , Anti-Inflamatórios/farmacologia , Linhagem Celular Tumoral , Curcuma/química , Serina Endopeptidases/metabolismo , COVID-19/virologia , COVID-19/metabolismo , Espécies Reativas de Oxigênio/metabolismo , Fator 2 Relacionado a NF-E2/metabolismo , Extratos Vegetais/farmacologia , Citocinas/metabolismo , NAD(P)H Desidrogenase (Quinona)/metabolismo , Neurônios/efeitos dos fármacos , Neurônios/metabolismo , Neurônios/virologia
2.
J Allergy Clin Immunol Glob ; 2(2): 100083, 2023 May.
Artigo em Inglês | MEDLINE | ID: mdl-36845213

RESUMO

Background: The pandemic unleashed by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected more than 500 million people worldwide and caused more than 6 million deaths. Cellular and humoral immunity induced by infection or immunization are key factors in controlling the viral burden and avoiding the recurrence of coronavirus disease. The duration and effectiveness of immunity after infection is relevant to pandemic policy interventions, including the timing of vaccine boosters. Objectives: We sought to evaluate longitudinal binding and functional antibodies against SARS-CoV-2 receptor-binding domain in police officers and health care workers with a history of coronavirus disease 2019 and compare with SARS-CoV-2-naive individuals after vaccination with adenovirus-based ChAdOx1 nCoV-19 (AstraZeneca-Fiocruz) or the inactivated CoronaVac vaccine (Sinovac-Butantan Institute). Methods: A total of 208 participants were vaccinated. Of these, 126 (60.57%) received the ChAdOx1 nCoV-19 vaccine and 82 (39.42%) received the CoronaVac vaccine. Prevaccination and postvaccination blood was collected, and the amount of anti-SARS-CoV-2 IgG and the neutralizing ability of the antibodies to block the interaction between angiotensin-converting enzyme 2 and receptor-binding domain were determined. Results: Subjects with preexisting SARS-CoV-2 immunity and who received a single dose of ChAdOx1 nCoV-19 or CoronaVac have similar or superior antibody levels when compared with levels in seronegative individuals even after 2 doses of the vaccine. Neutralizing antibody titers of seropositive individuals were higher with a single dose of either ChAdOx1 nCoV-19 or CoronaVac compared with those of seronegative individuals. After 2 doses, both groups reached a plateau response. Conclusions: Our data reinforce the importance of vaccine boosters to increase specific binding and neutralizing SARS-CoV-2 antibodies.

3.
Eur J Pharm Biopharm ; 180: 91-100, 2022 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-36154904

RESUMO

The use of graphene quantum dots as biomedical devices and drug delivery systems has been increasing. The nano-platform of pure carbon has shown unique properties and is approved to be safe for human use. In this study, we successfully produced and characterized folic acid-functionalized graphene quantum dots (GQD-FA) to evaluate their antiviral activity against Zika virus (ZIKV) infection in vitro, and for radiolabeling with the alpha-particle emitting radionuclide radium-223. The in vitro results exhibited the low cytotoxicity of the nanoprobe GQD-FA in Vero E6 cells and the antiviral effect against replication of the ZIKV infection. In addition, our findings demonstrated that functionalization with folic acid doesn't improve the antiviral effect of graphene quantum dots against ZIVK replication in vitro. On the other hand, the radiolabeled nanoprobe 223Ra@GQD-FA was also produced as confirmed by the Energy Dispersive X-Ray Spectroscopy analysis. 223Ra@GQD-FA might expand the application of alpha targeted therapy using radium-223 in folate receptor-overexpressing tumors.


Assuntos
Grafite , Pontos Quânticos , Infecção por Zika virus , Zika virus , Humanos , Pontos Quânticos/química , Grafite/química , Ácido Fólico/química , Antivirais/farmacologia
4.
Life Sci ; 308: 120930, 2022 Nov 01.
Artigo em Inglês | MEDLINE | ID: mdl-36075471

RESUMO

AIMS: This study evaluated SARS-CoV-2 replication in human cell lines derived from various tissues and investigated molecular mechanisms related to viral infection susceptibility and replication. MAIN METHODS: SARS-CoV-2 replication in BEAS-2B and A549 (respiratory tract), HEK-293 T (kidney), HuH7 (liver), SH-SY5Y (brain), MCF7 (breast), Huvec (endothelial) and Caco-2 (intestine) was evaluated by RT-qPCR. Concomitantly, expression levels of ACE2 (Angiotensin Converting Enzyme) and TMPRSS2 were assessed through RT-qPCR and western blot. Proteins related to autophagy and mitochondrial metabolism were monitored in uninfected cells to characterize the cellular metabolism of each cell line. The effect of ACE2 overexpression on viral replication in pulmonary cells was also investigated. KEY FINDINGS: Our data show that HuH7, Caco-2 and MCF7 presented a higher viral load compared to the other cell lines. The increased susceptibility to SARS-CoV-2 infection seems to be associated not only with the differential levels of proteins intrinsically related to energetic metabolism, such as ATP synthase, citrate synthase, COX and NDUFS2 but also with the considerably higher TMPRSS2 mRNA expression. The two least susceptible cell types, BEAS-2B and A549, showed drastically increased SARS-CoV-2 replication capacity when ACE2 was overexpressed. These modified cell lines are relevant for studying SARS-CoV-2 replication in vitro. SIGNIFICANCE: Our data not only reinforce that TMPRSS2 expression and cellular energy metabolism are important molecular mechanisms for SARS-CoV-2 infection and replication, but also indicate that HuH7, MCF7 and Caco-2 are suitable models for mechanistic studies of COVID-19. Moreover, pulmonary cells overexpressing ACE2 can be used to understand mechanisms associated with SARS-CoV-2 replication.


Assuntos
COVID-19 , Neuroblastoma , Trifosfato de Adenosina , Enzima de Conversão de Angiotensina 2/genética , Autofagia , Células CACO-2 , Citrato (si)-Sintase , Células HEK293 , Humanos , Peptidil Dipeptidase A/metabolismo , RNA Mensageiro/genética , SARS-CoV-2
5.
J Immunol Res ; 2021: 2939693, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-34604391

RESUMO

All extracellular forms of Trypanosoma cruzi, the causative agent of Chagas disease, release extracellular vesicles (EVs) containing major surface molecules of the parasite. EV release depends on several mechanisms (internal and external). However, most of the environmental conditions affecting this phenomenon are still unknown. In this work, we evaluated EV release under different stress conditions and their ability to be internalized by the parasites. In addition, we investigated whether the release conditions would affect their immunomodulatory properties in preactivated bone marrow-derived macrophages (BMDM). Sodium azide and methyl-cyclo-ß-dextrin (CDB) reduced EV release, indicating that this phenomenon relies on membrane organization. EV release was increased at low temperatures (4°C) and acidic conditions (pH 5.0). Under this pH, trypomastigotes differentiated into amastigotes. EVs are rapidly liberated and reabsorbed by the trypomastigotes in a concentration-dependent manner. Nitrosative stress caused by sodium nitrite in acid medium or S-nitrosoglutathione also stimulated the secretion of EVs. EVs released under all stress conditions also maintained their proinflammatory activity and increased the expression of iNOS, Arg 1, IL-12, and IL-23 genes in IFN-γ and LPS preactivated BMDM. In conclusion, our results suggest a budding mechanism of release, dependent on the membrane structure and parasite integrity. Stress conditions did not affect functional properties of EVs during interaction with host cells. EV release variations under stress conditions may be a physiological response against environmental changes.


Assuntos
Vesículas Extracelulares/imunologia , Macrófagos/imunologia , Estresse Fisiológico/imunologia , Trypanosoma cruzi/imunologia , Animais , Linhagem Celular , Células Cultivadas , Temperatura Baixa , Vesículas Extracelulares/metabolismo , Feminino , Regulação da Expressão Gênica/imunologia , Concentração de Íons de Hidrogênio , Imunidade/genética , Imunidade/imunologia , Interleucina-10/genética , Interleucina-10/imunologia , Interleucina-10/metabolismo , Macrófagos/metabolismo , Camundongos Endogâmicos C57BL , Óxido Nítrico Sintase Tipo II/genética , Óxido Nítrico Sintase Tipo II/imunologia , Óxido Nítrico Sintase Tipo II/metabolismo , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Nitrito de Sódio/metabolismo , Trypanosoma cruzi/metabolismo , Trypanosoma cruzi/fisiologia
6.
J Leukoc Biol ; 106(3): 581-594, 2019 09.
Artigo em Inglês | MEDLINE | ID: mdl-31299112

RESUMO

Chronic lymphocytic leukemia (CLL) is a chronic form of leukemia that originates from an abnormal expansion of CD5+ B-1 cells. Deregulation in the BCR signaling is associated with B-cell transformation. Contrariwise to B-2 cells, BCR engagement in B-1 cells results in low proliferation rate and increased apoptosis population, whereas overactivation may be associated with lymphoproliferative disorders. It has been demonstrated that several transcription factors that are involved in the B cell development play a role in the regulation of BCR function. Among them, Ikaros is considered an essential regulator of lymphoid differentiation and activation. Several reports suggest that Ikaros expression is deregulated in different forms of leukemia. Herein, we demonstrated that CLL cells show decreased Ikaros expression and abnormal cytoplasmic cell localization. These alterations were also observed in radioresistant B-1 cells, which present high proliferative activity, suggesting that abnormal localization of Ikaros could determine its loss of function. Furthermore, Ikaros knockdown increased the expression of BCR pathway components in murine B-1 cells, such as Lyn, Blnk, and CD19. Additionally, in the absence of Ikaros, B-1 cells become responsive to BCR stimulus, increasing cell proliferation even in the absence of antigen stimulation. These results suggested that Ikaros is an important controller of B-1 cell proliferation by interfering with the BCR activity. Therefore, altered Ikaros expression in CLL or radioresistant B-1 cells could determine a responsive status of BCR to self-antigens, which would culminate in the clonal expansion of B-1 cells.


Assuntos
Transformação Celular Neoplásica/genética , Regulação Leucêmica da Expressão Gênica , Fator de Transcrição Ikaros/genética , Leucemia Linfocítica Crônica de Células B/genética , Adulto , Idoso , Idoso de 80 Anos ou mais , Animais , Linfócitos B/imunologia , Transformação Celular Neoplásica/patologia , Citoplasma/metabolismo , Feminino , Humanos , Fator de Transcrição Ikaros/metabolismo , Leucemia Linfocítica Crônica de Células B/patologia , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Pessoa de Meia-Idade , Modelos Biológicos , Ligação Proteica , Tolerância a Radiação , Receptores de Antígenos de Linfócitos B/metabolismo , Transdução de Sinais
7.
Arq Bras Oftalmol ; 74(5): 338-42, 2011.
Artigo em Português | MEDLINE | ID: mdl-22183993

RESUMO

PURPOSE: To evaluate the comparative in-vitro antiangiogenic effect of Bevacizumab and Ranibizumab. METHODS: Endothelial venous umbilical cells culture (ECV304) cultivated in F12 media with addition of 10% Fetal Bovine Serum, were plaqued and treated with clinically relevant concentrations of Bevacizumab and Ranibizumab just after the scratch done in the middle of the culture (scratch methodology). Measurements of the linear size of the area free of cell proliferation were done 24, 48 and 72 hours after the scratch day point. All the experiments were done in triplicate and statistical analysis were done with T-student test. RESULTS: Inhibitory effect was observed just at the concentrations of 0.5 and 0.7 mg/ml in both drugs. At 0.7 mg/ml, Ranibizumab demonstrated a more potent proliferative inhibitory effect than Bevacizumab. At the same concentration, Ranibizumab was three times more potent than Ranibizumab. Inhibitory effect was observed just in the first 24 hours for both drugs. CONCLUSION: Ranibizumab demonstrates an increased effect when compared to Bevacizumab and this is related more to the different molar rate of each drug than related to a real better proliferative inhibitory effect.


Assuntos
Inibidores da Angiogênese/farmacologia , Anticorpos Monoclonais Humanizados/farmacologia , Proliferação de Células/efeitos dos fármacos , Células Endoteliais da Veia Umbilical Humana/efeitos dos fármacos , Bevacizumab , Células Cultivadas , Humanos , Ranibizumab , Fatores de Tempo
8.
Arq. bras. oftalmol ; Arq. bras. oftalmol;74(5): 338-342, set.-out. 2011. ilus
Artigo em Português | LILACS | ID: lil-608405

RESUMO

Objetivo: Comparar o efeito anti-angiogênico in vitro do Bevacizumab e do Rani bizumab. Métodos: Células endotelias venosas de cordão umbilical (ECV304), cultivadas em meio F12 com adição de 10 por cento de soro fetal bovino, foram plaqueadas e tratadas com concentrações clinicamente relevantes de Bevacizumab e Ranibizumab. As drogas foram administradas logo após risco realizado no meio da cultura (metodologia de scratch). Medidas lineares do espaço livre de proliferação celular foram realizadas 24, 48 e 72 horas após o momento da realização do risco. Todos os experimentos foram realizados em triplicata e a análise estatística foi feita pelo teste T-student. Resultados: O efeito inibitório foi observado em ambas as drogas, apenas nas concentrações 0,5 e 0,7 mg/ml. Na concentração 0,7 mg/ml, o Ranibizumab demonstrou efeito inibitório maior do que o Bevacizumab. Na mesma concentração, o Ranibizumab foi três vezes mais potente que o Bevacizumab. O efeito inibitório foi observado apenas nas primeiras 24 horas para ambas as drogas. Conclusão: O Ranibizumab demonstrou efeito maior quando comparado com o Bevacizumab, porém tal efeito está mais relacionado à diferença na razão molar das drogas do que relacionada com uma diferença real no efeito anti-proliferativo.


Purpose: To evaluate the comparative in-vitro antiangiogenic effect of Bevacizumab and Ranibizumab. Methods: Endothelial venous umbilical cells culture (ECV304) cultivated in F12 media with addition of 10 percent Fetal Bovine Serum, were plaqued and treated with clinically relevant concentrations of Bevacizumab and Ranibizumab just after the scratch done in the middle of the culture (scratch methodology). Measurements of the linear size of the area free of cell proliferation were done 24, 48 and 72 hours after the scratch day point. All the experiments were done in triplicate and statistical analysis were done with T-student test. Results: Inhibitory effect was observed just at the concentrations of 0.5 and 0.7 mg/ml in both drugs. At 0.7 mg/ml, Ranibizumab demonstrated a more potent proliferative inhibitory effect than Bevacizumab. At the same concentration, Ranibizumab was three times more potent than Ranibizumab. Inhibitory effect was observed just in the first 24 hours for both drugs. Conclusion: Ranibizumab demonstrates an increased effect when compared to Bevacizumab and this is related more to the different molar rate of each drug than related to a real better proliferative inhibitory effect.


Assuntos
Humanos , Inibidores da Angiogênese/farmacologia , Anticorpos Monoclonais Humanizados/farmacologia , Proliferação de Células/efeitos dos fármacos , Células Endoteliais da Veia Umbilical Humana/efeitos dos fármacos , Células Cultivadas , Fatores de Tempo
9.
Microbes Infect ; 13(3): 251-60, 2011 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-21070862

RESUMO

This work was conducted to identify virulence biomarkers for Paracoccidioides brasiliensis (Pb), the fungus responsible for Paracoccidioidomycosis (PCM), a systemic disease endemic in Latin America. Measurement of mortality showed that all B10.A mice were killed after 250 days by the virulent Pb18 isolate while only one of the mice that received the attenuated counterpart died. Also, number of lung CFUs from virulent Pb18 inoculated mice were much higher when these isolates were compared. Phage display methodology allowed selection of three phages that specifically bound to virulent Pb18. Variability of p04 phage binding to different Pb isolates were examples of variability of expression by the fungus of its binding molecule, strongly suggesting p04 as a biomarker of virulence. In vitro, its derived peptide pep04 killed only virulent fungi, and confocal microscopy showed that it was internalized only by the virulent isolate. Pep04 blocked establishment of Pb infection in mice and virulent Pb18 pre-incubated with p04 showed significantly inhibited lung infection. Furthermore, infected mice treated with p04 showed highly significant reduction in lung CFUs. These findings firmly establish p04 as a biomarker of Pb virulence. Therefore, after proper peptide engineering, p04 may become a useful adjuvant for the distressing treatment of PCM.


Assuntos
Antifúngicos/farmacologia , Paracoccidioides/efeitos dos fármacos , Peptídeos/farmacologia , Análise de Variância , Animais , Antifúngicos/metabolismo , Biomarcadores/análise , Biomarcadores/metabolismo , Contagem de Colônia Microbiana , Histocitoquímica , Fígado/microbiologia , Pulmão/microbiologia , Masculino , Camundongos , Microscopia de Fluorescência , Paracoccidioides/metabolismo , Biblioteca de Peptídeos , Peptídeos/metabolismo , Reprodutibilidade dos Testes , Baço/microbiologia , Virulência
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA